Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin

British Journal of Dermatology

Volumn 153, Issue 3, 2005, Pages 650-652

  Shergill, Bav ^a   Orteu, C H ^a   McBride, S R ^a   Rustin, M H A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Dementia; Intravenous immunoglobulin; Scleromyxoedema

Indexed keywords

ACID GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; OCTAPLAS; WARFARIN;

AGED; ARTICLE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CASE REPORT; COGNITIVE DEFECT; CONVULSION; DEMENTIA; DERMIS; DISEASE ASSOCIATION; DRUG MEGADOSE; HUMAN; KIDNEY DISEASE; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PSYCHOSIS; RARE DISEASE; RETINA HEMORRHAGE; RHEUMATIC DISEASE; SCLEROMYXEDEMA; SKIN DISEASE; SYMPTOMATOLOGY; TREATMENT OUTCOME;

AGED; DEMENTIA; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MYXEDEMA; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCLERODERMA, DIFFUSE; TREATMENT OUTCOME;

EID: 24344498730     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2005.06710.x     Document Type: Article

References (16)

1. Ronglioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44:273-81.
2. Webster G, Matsuoka L, Burchmore D. The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol 1993; 28:105-8.
3. Berger J, Dobbs M, Terhune M, Maragos W. The neurologic complications of scleromyxedema. Medicine 2001; 80:313-19.
4. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol 1995; 33:37-43.
5. Lister R, Jolles S, Whittaker S et al. Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). J Am Acad Dermatol 2000; 43:403-8.
6. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol 2004; 83:661-5.
7. Folstein MF, Folstein SE, McHugh PR. Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-98.
8. River Y, Levy I, Gilead L et al. Fever, convulsions and coma in scleromyxedema: a 'dermato-neuro syndrome'. Neurology 1996; 46:1178-9.
9. Feasel A, Donato M, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol 2001; 137:1071-2.
10. Johkura K, Susuki K, Hasegawa O et al. Encephalopathy in scleromyxedema. Neurology 1999; 53:1138-40.
11. Gonzalez J, Palangio M, Schwartz J et al. Scleromyxedema with dermato-neuro syndrome. J Am Acad Dermatol 2000; 42:927-8.
12. Ochitill H, Amberson J. Acute cerebral symptomatology, a rare presentation of scleromyxedema. J Clin Psychiatry 1978; 39:471-4.
13. Jepsen LV. Two cases of scleromyxedema. Acta Derm Venereol (Stockh) 1980; 60:77-9.
14. Cohn EJ, Hughes WL. Preparation and properties of serum and plasma proteins: a system for the separation into fractions of the protein and lipoprotein components of biological fluids. J Am Chem Soc 1946; 68:459-75.
15. Rutter GH. Requirements for safety and quality of intravenous immunoglobulin G preparations. J Neurol Neurosurg Psychiatry 1994; 57 (Suppl.):2-5.
16. Caradonna S, Jacobe H. Thalidomide as a potential treatment for scleromyxedema. Arch Dermatol 2004; 140:277-80.